Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01163643 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome
A Phase 2 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 356
- Enrollment target
NCT01163643 is a Phase 2 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 356 participants.
The verdict
NCT01163643, a Phase 2 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 356 participants
- Enrollment target
Study Summary
The objective of this study is to identify the concentration and daily dosing frequency of BOL-303242-X ophthalmic suspension in treating dry eye syndrome over a 12 week dosing period.
Interventions
- DRUG Placebo Comparator: Vehicle
- DRUG 0.3% BOL-303242-X ophthalmic suspension
- DRUG 2% BOL-303242-X ophthalmic suspension
- DRUG 1% BOL-303242-X ophthalmic suspension
- DRUG 2% BOL-303242-X ophthalmic suspension AM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 356 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01163643
The ClinicalTrials.gov registry entry for NCT01163643 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 356 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo Comparator: Vehicle is the first listed.
NCT01163643 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01163643 about?
NCT01163643 is a clinical study titled "Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome". The objective of this study is to identify the concentration and daily dosing frequency of BOL-303242-X ophthalmic suspension in treating dry eye syndrome over a 12 week dosing period.
What is the current status of trial NCT01163643?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 356 participants. The study started on 2010-07. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01163643?
The interventions under investigation include: Placebo Comparator: Vehicle (DRUG), 0.3% BOL-303242-X ophthalmic suspension (DRUG), 2% BOL-303242-X ophthalmic suspension (DRUG), 1% BOL-303242-X ophthalmic suspension (DRUG), 2% BOL-303242-X ophthalmic suspension AM (DRUG).
Who is sponsoring clinical trial NCT01163643?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.